ROCKVILLE, Md., Nov. 14, 2013 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused
on the prevention and treatment of serious infectious diseases,
today announced that SYN-004, Synthetic Biologics' product
candidate for the prevention of C. difficile infections, was
selected as a 2013 Top Project to Watch in the infectious disease
area. This selection was made through Elsevier Business
Intelligence's panel of independent experts who screen hundreds of
compounds and weigh their potential as future products. The Company
also announced that Jeffrey Riley,
CEO, will present at the 2013 Therapeutic Area Partnerships
Conference on Tuesday, November 19,
2013 at 4:00pm (EST) at the
Hyatt Regency in Boston.
(Logo:
http://photos.prnewswire.com/prnh/20130522/MM19465LOGO)
Mr. Riley, as well as Synthetic Biologics' CFO, C. Evan Ballantyne, will be available to
participate in one-on-one meetings with conference attendees on
Tuesday and Wednesday, November 19
and 20, 2013.
About Elsevier Business Intelligence and the Therapeutic Area
Partnerships Conference
Elsevier Business Intelligence provides business intelligence on
regulatory, business and reimbursement issues that are vital to the
healthcare industry. Through a range of products including
publications, conferences, databases and reports, Elsevier Business
Intelligence places biopharma and medical device professionals, and
those who focus on these industries, at the forefront of knowledge,
by providing a combination of news and information together with
penetrating insight and analysis.
Organized by Elsevier Business Intelligence, the 2013
Therapeutic Area Partnerships (TAP) conference is designed to bring
together biopharmaceutical industry decision makers to assess the
most promising drug programs available for partnering in the
following therapeutic areas: oncology, cardiovascular/metabolic
diseases, neuroscience, infectious diseases,
anti-inflammatory/autoimmune diseases and advanced therapies. For
more information, please visit the conference website at
http://www.elsevierbi.com/mkt/Conf/TAP2013/PresentingCos.
About Synthetic Biologics, Inc.
Synthetic Biologics (NYSE MKT: SYN) is a biotechnology company
focused on the development of biologics for the prevention and
treatment of serious infectious diseases. The Company is developing
an oral enzyme for the prevention of C. difficile
infections, and a series of monoclonal antibody therapies for the
treatment of Pertussis and Acinetobacter infections.
In addition, the Company is developing a drug candidate for the
treatment of relapsing-remitting multiple sclerosis and cognitive
dysfunction in multiple sclerosis. For more information, please
visit Synthetic Biologics' website at
www.syntheticbiologics.com.
To download Synthetic Biologics' investor relations mobile
device app, which allows users access to the Company's SEC
documents, press releases and events, please click on the following
links to download the IRapp on your iPhone and iPad or your Android
mobile device.
SOURCE Synthetic Biologics, Inc.